Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Inclusion Criteria: * Capable of giving signed informed consent. * Participants who have completed Study IKT-001-201 or any other Phase 2 or 3 controlled clinical study with IKT-001. Exclusion Criteria: * Any of the following clinical laboratory values at screening: * ALT or AST levels \>3× the ULN * Bilirubin levels \>2× the ULN * ANC \<1.2 ×10\^9 cells/L, hemoglobin \<9 g/dL, hematocrit \<30%, or platelets \<75 × 10\^9 cells/L * Absolute eGFR \<30 mL/min using creatinine or cystatin C as defined by the CKD-EPI equation (2021) * Currently lactating, pregnant or planning on becoming pregnant during the study. * Receiving treatment with sotatercept.